Eton Pharmaceuticals, Inc. (ETON) Investor Relations Documents
Eton Pharmaceuticals, Inc. (ETON) investor relations documents from the company's IR site: 1 presentation, 22 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.
Corporate Presentation: Eton Pharmaceuticals' August 2026 presentation outlines a vision for the largest US ultra-rare disease portfolio, projecting over $500M peak sales through acquisitions and
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-14 | Presentation | Corporate Presentation |
| 2026-08-13 | Press release | Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results |
| 2026-08-05 | Press release | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candid |
| 2026-08-03 | Press release | Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 |
| 2026-07-29 | Press release | Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone |
| 2026-05-19 | Press release | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (mi |
| 2026-05-14 | Press release | Eton Pharmaceuticals Reports First Quarter 2026 Financial Results |
| 2026-05-04 | Press release | Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 |
| 2026-05-01 | Press release | Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy |
| 2026-04-27 | Press release | Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 |
| 2026-04-16 | Press release | Eton Pharmaceuticals Announces CFO Succession Plan |
| 2026-03-19 | Press release | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-03 | Press release | Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 |
| 2026-03-02 | Press release | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® ( |
| 2026-02-25 | Press release | Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution |
| 2026-02-20 | Press release | Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th |
| 2026-02-02 | Press release | Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate |
| Press release | Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| Press release | Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 |
| Press release | Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results |
| Press release | Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 |
| Press release | Eton Pharmaceuticals Reports First Quarter 2025 Financial Results |
| Press release | Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 |
ETON overview · ETON earnings · ETON financials · ETON KPIs · ETON documents · ETON ownership · ETON peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.